EGFR and non-small cell lung carcinoma: This pattern reflects previous findings among patients that PFS was regarded as the most important attribute in EGFR‐mutated NSCLC treatments, and mode of administration (oral or IV) was the least important among other attributes depicting side effects (e.g., rash, diarrhea, nausea, and vomiting).15